Spirituality, Religiosity, and Immune Functioning - Full Text View

Spirituality, Religiosity, and Immune Functioning

This study has been completed.

Sponsored by:	National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by:	National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier:	NCT00066924

Purpose

The purpose of this study is to determine whether religiosity and spirituality are related to immune functioning, as measured by interleukin-6 blood plasma level, among terminally ill cancer patients.

Condition

Cancer
Depression
Dying Process

MedlinePlus related topics:

Cancer Depression

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Cross-Sectional, Defined Population, Prospective Study

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment:	120
Study Start Date:	September 2003
Estimated Study Completion Date:	June 2004

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Inpatient at Calvary Hospital
Diagnosis of terminal cancer
Score of 20 or above on Mini-Mental State Exam

Exclusion criteria:

Presence of a psychiatric disorder that would preclude the production of meaningful data

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00066924

Locations


United States, New York
	Calvary Hospital
	Bronx, New York, United States

Sponsors and Collaborators

National Center for Complementary and Alternative Medicine (NCCAM)

Investigators


Principal Investigator:	Barry Rosenfeld, PhD	Fordham University, Psychology dept

Principal Investigator:	William Breitbart, MD	Memorial Sloan-Kettering Cancer Center

More Information

Publications:

McClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet. 2003 May 10;361(9369):1603-7.

Study ID Numbers:	F31 AT001769-01
First Received:	August 7, 2003
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00066924
Health Authority:	United States: Federal Government